ANI Pharmaceuticals (NASDAQ:ANIP) Price Target Raised to $94.00 at HC Wainwright

ANI Pharmaceuticals (NASDAQ:ANIP) had its price target increased by HC Wainwright from $87.00 to $94.00 in a report released on Wednesday, Benzinga reports. They currently have a buy rating on the specialty pharmaceutical company’s stock.

Several other research analysts have also issued reports on ANIP. Truist Financial boosted their target price on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a buy rating in a research report on Friday, March 1st. Guggenheim reiterated a buy rating and set a $77.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday, April 23rd. Finally, Capital One Financial started coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 15th. They set an overweight rating and a $80.00 target price for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, ANI Pharmaceuticals currently has an average rating of Buy and a consensus price target of $82.75.

ANI Pharmaceuticals Price Performance

Shares of ANI Pharmaceuticals stock opened at $65.49 on Wednesday. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of 40.93 and a beta of 0.81. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.12 and a current ratio of 3.95. The stock has a 50 day moving average price of $64.28 and a 200-day moving average price of $61.59. ANI Pharmaceuticals has a one year low of $48.20 and a one year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, May 10th. The specialty pharmaceutical company reported $0.95 EPS for the quarter, topping the consensus estimate of $0.79 by $0.16. ANI Pharmaceuticals had a net margin of 6.87% and a return on equity of 17.15%. The company had revenue of $137.43 million during the quarter, compared to analyst estimates of $125.01 million. Equities analysts expect that ANI Pharmaceuticals will post 3.34 EPS for the current year.

Insider Transactions at ANI Pharmaceuticals

In related news, COO Muthusamy Shanmugam sold 20,000 shares of the company’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $58.90, for a total value of $1,178,000.00. Following the completion of the sale, the chief operating officer now directly owns 682,620 shares of the company’s stock, valued at $40,206,318. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CFO Stephen P. Carey sold 5,000 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $63.58, for a total value of $317,900.00. Following the transaction, the chief financial officer now directly owns 161,968 shares in the company, valued at approximately $10,297,925.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Muthusamy Shanmugam sold 20,000 shares of the company’s stock in a transaction on Friday, June 21st. The stock was sold at an average price of $58.90, for a total value of $1,178,000.00. Following the sale, the chief operating officer now owns 682,620 shares of the company’s stock, valued at $40,206,318. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 176,688 shares of company stock valued at $11,408,863. 12.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Pacer Advisors Inc. purchased a new stake in ANI Pharmaceuticals during the fourth quarter valued at approximately $41,000. AJOVista LLC purchased a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at $58,000. SG Americas Securities LLC acquired a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth $106,000. China Universal Asset Management Co. Ltd. grew its stake in ANI Pharmaceuticals by 361.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,367 shares of the specialty pharmaceutical company’s stock worth $131,000 after buying an additional 1,854 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in ANI Pharmaceuticals during the 4th quarter valued at about $132,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.